Nanoformulation of natural products for prevention and therapy of prostate cancer

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 142-151

  Sanna, Vanna ^a,b   Siddiqui, Imtiaz A ^a   Sechi, Mario ^a,b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Nanochemoprevention; Nanoparticles; Natural products; Prostate cancer; PSMA; Targeted nanoparticles

Indexed keywords

BIND 014; CREMOPHOR; CURCUMIN; DOCETAXEL; EPIGALLOCATECHIN GALLATE; FIBRINOGEN; GOLD NANOPARTICLE; MACROGOL; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PLANT MEDICINAL PRODUCT; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; POLYPHENOL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RESVERATROL; TRANSFERRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TAXOID;

ANTIPROLIFERATIVE ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CURCUMA; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; NANODEVICE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; SHORT SURVEY; TEA; ANIMAL; MALE; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NANOTECHNOLOGY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84891913769     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.037     Document Type: Review

References (143)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics. CA. Cancer J. Clin. 2012, 62:220-241.
3. Syed D.N., Khan N., Afaq F., Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2193-2203.
4. Donaldson M.S. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr. J. 2004, 3:19.
5. Siddiqui I.A., Saleem M., Adhami V.M., Asim M., Mukhtar H. Tea beverage in chemoprevention and chemotherapy of prostate cancer. Acta Pharmacol. Sin. 2007, 28:1392-1408.
6. Siddiqui I.A., Afaq F., Adhami V.M., Mukhtar H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen. Chem. Biol. Interact. 2008, 171:122-132.
7. Mukhtar H. Chemoprevention: making it a success story for controlling human cancer. Cancer Lett. 2012, 326:123-127.
8. Khan N., Adhami V.M., Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr. Relat. Cancer 2010, 17:R39-52.
9. Wilson K.M., Giovannucci E.L., Mucci L.A. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J. Androl. 2012, 14:365-374.
10. Marshall J.R. Diet and prostate cancer prevention. World J. Urol. 2012, 30:157-165.
11. Ledesma M.C., Jung-Hynes B., Schmit T.L., Kumar R., Mukhtar H., Ahmad N. Selenium and vitamin E for prostate cancer: post-SELECT (selenium and vitamin E cancer prevention trial) status. Mol. Med. 2011, 17:134-143.
12. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., Ahmad N., Cui H., Mousa S.A., Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69:1712-1716.
13. Khan N., Afaq F., Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal. 2008, 10:475-510.
14. Fujiki H., Suganuma M. Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett. 2012, 324:119-125.
15. Connors S.K., Chornokur G., Kumar N.B. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr. Cancer 2012, 64:4-22.
16. Siddiqui I.A., Adhami V.M., Saleem M., Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 2006, 50:130-143.
17. Adhami V.M., Ahmad N., Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J. Nutr. 2003, 133:2417S-2424S.
18. Gupta S., Ahmad N., Mohan R.R., Husain M.M., Mukhtar H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res. 1999, 59:2115-2120.
19. Thomas F., Patel S., Holly J.M., Persad R., Bahl A., Perks C.M. Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 2009, 69:219-224.
20. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27:2055-2063.
21. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., Afaq F., Pasha F.S., Saleem M., Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2007, 13:1611-1619.
22. Hastak K., Agarwal M.K., Mukhtar H., Agarwal M.L. Ablation of either p21 or bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J. 2005, 19:789-791.
23. Adhami V.M., Siddiqui I.A., Sarfaraz S., Khwaja S.I., Hafeez B.B., Ahmad N., Mukhtar H. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin. Cancer Res. 2009, 15:1947-1953.
24. Gupta S., Hastak K., Ahmad N., Lewin J.S., Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. USA 2001, 98:10350-10355.
25. Siddiqui I.A., Shukla Y., Adhami V.M., Sarfaraz S., Asim M., Hafeez B.B., Mukhtar H. Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm. Res. 2008, 25:2135-2142.
26. Yuan J.M., Sun C., Butler L.M. Tea and cancer prevention: epidemiological studies. Pharmacol. Res. 2011, 64:123-135.
27. Khan N., Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem. Pharmacol. 2012.
28. Khan N., Adhami V.M., Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr. Cancer 2009, 61:836-841.
29. Johnson J.J., Bailey H.H., Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 2010, 17:3-13.
30. Aziz M.H., Reagan-Shaw S., Wu J., Longley B.J., Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?. FASEB J. 2005, 19:1193-1195.
31. Aziz M.H., Kumar R., Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol. 2003, 23:17-28.
32. Bhat K.P., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci. 2002, 957:210-229.
33. Harada N., Atarashi K., Murata Y., Yamaji R., Nakano Y., Inui H. Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: implication of DNA binding and acetylation of the receptor. J. Steroid Biochem. Mol. Biol. 2011, 123:65-70.
34. Hsieh T.C., Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 1999, 249:109-115.
35. Jeong N.Y., Yoon Y.G., Rho J.H., Lee J.S., Lee S.Y., Yoo K.S., Song S., Suh H., Choi Y.H., Yoo Y.H. The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int. J. Oncol. 2011, 38:1597-1604.
36. Kai L., Levenson A.S. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res. 2011, 31:3323-3330.
37. Shankar S., Chen Q., Siddiqui I., Sarva K., Srivastava R.K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J. Mol. Signal. 2007, 2:7.
38. Shankar S., Siddiqui I., Srivastava R.K. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol. Cell. Biochem. 2007, 304:273-285.
39. Johnson J.J., Nihal M., Siddiqui I.A., Scarlett C.O., Bailey H.H., Mukhtar H., Ahmad N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011, 55:1169-1176.
40. Athar M., Back J.H., Kopelovich L., Bickers D.R., Kim A.L. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009, 486:95-102.
41. Klempner S.J., Bubley G. Complementary and alternative medicines in prostate cancer: from bench to bedside?. Oncologist 2012, 17:830-837.
42. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
43. Amri A., Chaumeil J.C., Sfar S., Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Control. Release: Off. J. Control. Release Soc. 2012, 158:182-193.
44. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 2007, 595:1-75.
45. Aggarwal B.B. Prostate cancer and curcumin: add spice to your life. Cancer Biol. Ther. 2008, 7:1436-1440.
46. Teiten M.H., Gaascht F., Eifes S., Dicato M., Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010, 5:61-74.
47. Khor T.O., Keum Y.S., Lin W., Kim J.H., Hu R., Shen G., Xu C., Gopalakrishnan A., Reddy B., Zheng X., Conney A.H., Kong A.N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 2006, 66:613-621.
48. Dorai T., Gehani N., Katz A. Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 2000, 3:84-93.
49. Dorai T., Cao Y.C., Dorai B., Buttyan R., Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001, 47:293-303.
50. Hong J.H., Ahn K.S., Bae E., Jeon S.S., Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 2006, 9:147-152.
51. Shankar S., Chen Q., Sarva K., Siddiqui I., Srivastava R.K. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J. Mol. Signal. 2007, 2:10.
52. Thangapazham R.L., Shaheduzzaman S., Kim K.H., Passi N., Tadese A., Vahey M., Dobi A., Srivastava S., Maheshwari R.K. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol. Ther. 2008, 7:1427-1435.
53. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., Pirmohamed M., Marnett L.J., Gescher A.J., Steward W.P. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7:1894-1900.
54. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
55. Rozzi A., Nardoni C., Corona M., Restuccia M.R., Falbo T., Lanzetta G. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non-small cell lung cancer (NSCLC): results of a phase II study. J. Chemother. 2011, 22:419-423.
56. Gupta S.C., Kim J.H., Prasad S., Aggarwal B.B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastas. Rev. 2010, 29:405-434.
57. Wu Y.Y., Chang J.Y., Chao T.Y. Paclitaxel and carboplatin-induced complete remission in peritoneal carcinomatosis of unknown origin: a report of two cases and review of the literature. Tumori 2010, 96:336-339.
58. George J., Banik N.L., Ray S.K. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J. Cell Mol. Med. 2009, 13:4205-4218.
59. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994, 344:1267-1272.
60. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008, 26:242-245.
61. Smith D.C., Pienta K.J. Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin. Oncol. 1999, 26:109-111.
62. Eymard J.C., Priou F., Zannetti A., Ravaud A., Lepille D., Kerbrat P., Gomez P., Paule B., Genet D., Herait P., Ecstein-Fraisse E., Joly F. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann. Oncol. 2007, 18:1064-1070.
63. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
64. van Zuylen L., Verweij J., Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 2001, 19:125-141.
65. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann. Oncol. 2006, 17:735-749.
66. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8:1038-1044.
67. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63:185-198.
68. Kim B.Y., Rutka J.T., Chan W.C. Nanomedicine. N. Engl. J. Med. 2010, 363:2434-2443.
69. Doane T.L., Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev. 2012, 41:2885-2911.
70. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
71. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
72. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 2010, 128:324-335.
73. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
74. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
75. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
76. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol. Cells 2011, 31:295-302.
77. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 2011, 44:979-989.
78. Zhang X.Q., Xu X., Bertrand N., Pridgen E., Swami A., Farokhzad O.C. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv. Drug Deliv. Rev. 2012.
79. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine - challenge and perspectives. Angew. Chem. Int. Ed. Engl. 2009, 48:872-897.
80. Sanna V., Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 2012, 73:27-32.
81. Sanna V., Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine: Nanotechnol., Biol., Med. 2012, 8(Suppl 1):S31-S36.
82. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 2011, 44:1123-1134.
83. Ranganathan R., Madanmohan S., Kesavan A., Baskar G., Krishnamoorthy Y.R., Santosham R., Ponraju D., Rayala S.K., Venkatraman G. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int. J. Nanomed. 2012, 7:1043-1060.
84. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
85. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1615-1626.
86. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
87. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
88. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607-4612.
89. Yatvin M.B., Kreutz W., Horwitz B.A., Shinitzky M. PH-sensitive liposomes: possible clinical implications. Science 1980, 210:1253-1255.
90. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
91. Siu D. Cancer therapy using tumor-associated antigens to reduce side effects. Clin. Exp. Med. 2009, 9:181-198.
92. Schulke N., Varlamova O.A., Donovan G.P., Ma D., Gardner J.P., Morrissey D.M., Arrigale R.R., Zhan C., Chodera A.J., Surowitz K.G., Maddon P.J., Heston W.D., Olson W.C. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. USA 2003, 100:12590-12595.
93. Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91:528-539.
94. Zhou J., Neale J.H., Pomper M.G., Kozikowski A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov. 2005, 4:1015-1026.
95. Barinka C., Rovenska M., Mlcochova P., Hlouchova K., Plechanovova A., Majer P., Tsukamoto T., Slusher B.S., Konvalinka J., Lubkowski J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J. Med. Chem. 2007, 50:3267-3273.
96. Barinka C., Byun Y., Dusich C.L., Banerjee S.R., Chen Y., Castanares M., Kozikowski A.P., Mease R.C., Pomper M.G., Lubkowski J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem. 2008, 51:7737-7743.
97. Mesters J.R., Barinka C., Li W., Tsukamoto T., Majer P., Slusher B.S., Konvalinka J., Hilgenfeld R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006, 25:1375-1384.
98. Davis M.I., Bennett M.J., Thomas L.M., Bjorkman P.J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. USA 2005, 102:5981-5986.
99. Siddiqui I.A., Adhami V.M., Ahmad N., Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr. Cancer 2010, 62:883-890.
100. Siddiqui I.A., Mukhtar H. Nanochemoprevention by bioactive food components: a perspective. Pharm. Res. 2010, 27:1054-1060.
101. Sanna V., Pintus G., Roggio A.M., Punzoni S., Posadino A.M., Arca A., Marceddu S., Bandiera P., Uzzau S., Sechi M. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J. Med. Chem. 2011, 54:1321-1332.
102. Maresca K.P., Hillier S.M., Femia F.J., Keith D., Barone C., Joyal J.L., Zimmerman C.N., Kozikowski A.P., Barrett J.A., Eckelman W.C., Babich J.W. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem. 2009, 52:347-357.
103. Rocha S., Generalov R., Pereira Mdo C., Peres I., Juzenas P., Coelho M.A. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine (Lond.) 2011, 6:79-87.
104. Nune S.K., Chanda N., Shukla R., Katti K., Kulkarni R.R., Thilakavathi S., Mekapothula S., Kannan R., Katti K.V. Green nanotechnology from tea: phytochemicals in tea as building blocks for production of biocompatible gold nanoparticles. J. Mater. Chem. 2009, 19:2912-2920.
105. Shukla R., Chanda N., Zambre A., Upendran A., Katti K., Kulkarni R.R., Nune S.K., Casteel S.W., Smith C.J., Vimal J., Boote E., Robertson J.D., Kan P., Engelbrecht H., Watkinson L.D., Carmack T.L., Lever J.R., Cutler C.S., Caldwell C., Kannan R., Katti K.V. Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109:12426-12431.
106. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 2009, 125:1-8.
107. Mukerjee A., Vishwanatha J.K. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009, 29:3867-3875.
108. Thangapazham R.L., Puri A., Tele S., Blumenthal R., Maheshwari R.K. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 2008, 32:1119-1123.
109. Yallapu M.M., Dobberpuhl M.R., Maher D.M., Jaggi M., Chauhan S.C. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr. Drug Metab. 2012, 13:120-128.
110. Rejinold N.S., Muthunarayanan M., Chennazhi K.P., Nair S.V., Jayakumar R. Curcumin loaded fibrinogen nanoparticles for cancer drug delivery. J. Biomed. Nanotechnol. 2011, 7:521-534.
111. Zheng D., Wang Y., Zhang D., Liu Z., Duan C., Jia L., Wang F., Liu Y., Liu G., Hao L., Zhang Q. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett. 2011, 307:158-164.
112. Leonarduzzi G., Testa G., Sottero B., Gamba P., Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr. Med. Chem. 2010, 17:74-95.
113. Siddiqui I.A., Adhami V.M., Chamcheu J.C., Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int. J. Nanomed. 2012, 7:591-605.
114. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA 2008, 105:2586-2591.
115. Gu F., Langer R., Farokhzad O.C. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol. Biol. 2009, 544:589-598.
116. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103:6315-6320.
117. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64:7668-7672.
118. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., Levy-Nissenbaum E., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
119. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 2012, 41:2971-3010.
120. Chandran S.S., Banerjee S.R., Mease R.C., Pomper M.G., Denmeade S.R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther. 2008, 7:974-982.
121. Sanna V., Roggio A.M., Posadino A.M., Cossu A., Marceddu S., Mariani A., Alzari V., Uzzau S., Pintus G., Sechi M. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res. Lett. 2011, 6:260.
122. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 2004, 112:335-340.
123. Goldstein D., Gofrit O., Nyska A., Benita S. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. Cancer Res. 2007, 67:269-275.
124. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 2010, 18:53-58.
125. Ling Y., Wei K., Luo Y., Gao X., Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32:7139-7150.
126. Feng L., Wu H., Ma P., Mumper R.J., Benhabbour S.R. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo. Int. J. Nanomed. 2011, 6:2545-2556.
127. Tong R., Yala L., Fan T.M., Cheng J. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials 2010, 31:3043-3053.
128. Hua M.Y., Yang H.W., Chuang C.K., Tsai R.Y., Chen W.J., Chuang K.L., Chang Y.H., Chuang H.C., Pang S.T. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31:7355-7363.
129. Cervin C., Tinzl M., Johnsson M., Abrahamsson P.A., Tiberg F., Dizeyi N. Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. Eur. J. Pharm. Sci. 2010, 41:369-375.
130. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J.J., Song Y.H., Summa J., Tompsett D., Troiano G., Van Geen Hoven T., Wright J., LoRusso P., Kantoff P.W., Bander N.H., Sweeney C., Farokhzad O.C., Langer R., Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Translational Med. 2012, 4:128ra139.
131. Zhao P., Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem 2012, 7:952-972.
132. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., Tan W., Fitch T.R., Rowland K.M., Young C.Y., Flynn P.J. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442-1446.
133. Choan E., Segal R., Jonker D., Malone S., Reaume N., Eapen L., Gallant V. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urologic Oncol. 2005, 23:108-113.
134. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a 1-year proof-of-principle study. Cancer Res. 2006, 66:1234-1240.
135. Brausi M., Rizzi F., Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: 2 years later. A follow-up update. Eur. Urol. 2008, 54:472-473.
136. McLarty J., Bigelow R.L., Smith M., Elmajian D., Ankem M., Cardelli J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. (Phila.) 2009, 2:673-682.
137. Nguyen M.M., Ahmann F.R., Nagle R.B., Hsu C.H., Tangrea J.A., Parnes H.L., Sokoloff M.H., Gretzer M.B., Chow H.H. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev. Res. (Phila.) 2012, 5:290-298.
138. Ravi Kumar M.N. Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines?. Drug Discov. Today 2012, 17:407-408.
139. Kaplan S.A., Roehrborn C.G., Meehan A.G., Liu K.S., Carides A.D., Binkowitz B.S., Heyden N.L., Vaughan E.D. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009, 73:935-939.
140. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., Bolognese J.A., Oxenius B., Horgan K., Loftus S., Morton D.G. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
141. Goss P.E., Ingle J.N., Ales-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., McTiernan A., Robbins J., Johnson K.C., Martin L.W., Winquist E., Sarto G.E., Garber J.E., Fabian C.J., Pujol P., Maunsell E., Farmer P., Gelmon K.A., Tu D., Richardson H. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 2011, 364:2381-2391.
142. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1450.
143. Zu Y.G., Yuan S., Zhao X.H., Zhang Y., Zhang X.N., Jiang R. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticle. Yao xue xue bao = Acta pharmaceutica Sinica 2009, 44:525-531.